Table 3
|
Interpretation of PPVs and LRs+ of APOE alleles and genotypes |
||||
| allele/genotype |
PPV [ (AD|ε)] |
LR+ |
LR range1 |
Significance for diagnosis |
|
|
||||
| > 10 |
greatly increasing risk for AD |
|||
| 5~ 10 |
moderately increasing risk for AD |
|||
| ε4/ε4 |
39.90% |
3.76 |
2~ 5 |
small increase in risk for AD |
| ε4 |
31.50% |
2.60 |
||
| ε3/ε4 |
28.80% |
2.29 |
||
| 1~ 2 |
minimally increasing risk for AD |
|||
| 15.00% (population prevalence) |
1 |
no change in risk for AD |
||
| ε3 |
12.00% |
0.77 |
0.5~ 1 |
minimally decreasing risk for AD |
| ε2/ε4 |
10.82% |
0.69 |
||
| ε3/ε3 |
9.40% |
0.59 |
||
| ε2 |
6.50% |
0.39 |
0.2~ 0.5 |
small decrease in risk for AD |
| ε2/ε3 |
5.70% |
0.34 |
||
| 0.1~ 0.2 |
moderately decreasing risk for AD |
|||
| < 0.1 |
greatly decreasing risk for AD |
|||
|
PPV, estimated positive predictive value; LR+, positive likelihood ratios. 1Reference to [39]. | ||||
Zuo et al. Behavioral and Brain Functions 2006 2:13 doi:10.1186/1744-9081-2-13 |
||||